header logo image


Page 1,080«..1020..1,0791,0801,0811,082..1,0901,100..»

Stem Cell Therapy receives FDA Boost to enter the US Market – Labiotech.eu (blog)

March 7th, 2017 6:41 pm

TiGenix has receivedpositive feedback from the FDA on an improved global phase III trial protocol for its lead candidateCx601 for Crohns disease. This is expected tospeed up US approval.

TiGenix is a Belgian companydevelopingstem cell therapies. The biotech is currently pushing its lead candidateCx601to the market for the treatment ofcomplex perianal fistulas in Crohns disease patients. Cx601 recently revealedpositive resultsin a European phase III study.

Following these results, the company submitted a number of technical adjustments for itspivotal phase III study for Biologics License Application (BLA) in the US, which were now approved by the FDA and are expected to acceleratethe process to US marketing authorization.

TiGenix is wellknown for its productChondroCellect, which was the first cell therapyto reach approval on the European market for the repair of knee cartilage.After the companyrecently withdrew its market authorization for this product, due to a lack of reimbursement, the biotech is focusing on its new leadCx601.

Thisproduct, currently awaiting EMA approval, consists ofallogeneic expanded adipose-derived stem cells (eASC), which are indicated for the treatment ofperianal fistulas in Crohns disease. The therapeuticeffects of eASCs are based on immunomodulatory abilities of these stem cells, which canrestore immune balance by suppressing a variety of immune cell subsets and inducing the generation of regulatory T cells.

Areas of the colon commonly affected duringCrohns disease

The current approval from the FDA will allow TiGenix to file the BLAbased on the efficacy and safety follow-up of patients at week 24, instead of week 52.The FDA has also agreed to accept fewer patients than originally planned in the study and endorsed a broader target population that will ultimately facilitate the recruitment process.

We believe that this revised protocol will allow us to file for approval one year earlier than we had originally plannedconcludedMaria Pascual, VP Regulatory Affairs & Corporate Quality of TiGenix

The current amendments will allow TiGenix to push its therapyto the US market even faster, which might pivotal for the company in light of its financial situation. After its shares had reached a low of22 cents back in 2013, the share price is currently still under 1. Withits low 34M IPO on Nasdaq in the end of last year, its market cap is stillonly at 191M. A low sum for a late stage clinical company.

As the EMAapproval forCx601 is expected soon, which will then be commercialized by Takeda, the company may actually be underestimated. The biotech recently started a new Phase Ib/IIa trial to testCx611 as a treatment for sepsis in patients with pneumonia.

Asecond platform consisting of transplanted allogeneic cardiac stem cells (AlloCSC)is currently in Phase II for acute myocardial infarction. It seems like TiGenix is definitely clinging toits position as one of the pioneers in stem cell-based therapies.

Images via shutterstock.com / CI Photos and CC 3.0 /RicHard-59

More here:
Stem Cell Therapy receives FDA Boost to enter the US Market - Labiotech.eu (blog)

Read More...

Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source – Global Forecasts to 2021 – Yahoo Finance

March 7th, 2017 6:41 pm

NEW YORK, March 7, 2017 /PRNewswire/ -- l stem cell therapy market is estimated to grow at a CAGR of 11.0% during 2016 to 2021 to reach USD 145.8 million by 2021. Growth in the global stem cell therapy market is driven by factors such as the growing awareness of the therapeutic potency of stem cells in effective disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for development of stem cell therapies, identification of new stem cell lines, and developments in infrastructure related to stem cell banking and processing. In addition, countries such as Japan, South Korea, and China are offering new growth opportunities for players operating in this market. The North American region is expected to command the largest share in the stem cell therapy market in 2016.

Read the full report: http://www.reportlinker.com/p04759526-summary/view-report.html

Based on the type of therapy, the allogeneic stem cell therapy segment is estimated to command the larger share of the global stem cell therapy market in 2016. This growth can be attributed to the growing availability of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easier production scale-up due to easy availability of sources of stem cells, and growing number of clinical trials of allogeneic stem cell therapies as compared to autologous stem cell therapies.

The stem cell therapy market is niche industry with a growing number of global and local companies involved in the development and commercialization of stem cell therapy products. Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), and Pharmicell Co., Ltd. (South Korea) were the leading players in the global stem cell therapy market in 2015. New product launches and approvals; expansions; and partnerships and agreements are the major strategies adopted by most of the market players to achieve growth in the stem cell therapy market during 20132016.

Research Coverage This report studies stem cell therapy market based on type of therapy (allogeneic and autologous). These stem cell therapies are used for the treatment of various diseases (including musculoskeletal disorders, wound healing, CVDs, and GI diseases, among others). The report also studies, the factors (such as drivers, restraints, opportunities, and challenges) which affect the market growth in a positive and negative manner. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report forecasts the revenue of the market segments with respect to four main regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World. The stem cell therapy market report strategically profiles the key players who are involved in the manufacturing and commercialization of stem cell therapy products and comprehensively analyze their market ranking and core competencies. The report tracks and analyzes competitive developments such as new product launches and enhancements; expansions; and partnerships and agreements in the stem cell therapy market.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysismarket share analysis of the top players and company profiles, which together comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the stem cell therapy market; and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on products offered by the top 10 players in the stem cell therapy market. The report analyzes the stem cell therapy market by type, therapeutic application, cell source, and region

- Product Development/Innovation: Detailed insights on research and development activities, developmental product pipeline, and new product launches in the stem cell therapy market

- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various stem cell therapy products across four geographies (North America, Europe, Asia-Pacific, and the Rest of the World)

- Competitive Assessment: Assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the stem cell therapy market

Read the full report: http://www.reportlinker.com/p04759526-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Read More

Read the rest here:
Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source - Global Forecasts to 2021 - Yahoo Finance

Read More...

Stem Cell Therapy An Option For ENC Patients – Public Radio East

March 7th, 2017 6:41 pm

Stem cell therapy is a quickly advancing treatment being used across the country. Now, its becoming more prevalent in eastern North Carolina to those living with chronic pain an alternative to surgery. The minimally invasive procedure is showing results in alleviating back, knee, hip and shoulder pain. Though stem cell therapy is classified by the Food and Drug Administration as experimental, patients say theyre finding relief. Meet New Bern resident and a local endodontist Dr. Donnie Luper. He was skeptical of the procedure at first.

How did you know what those stem cells were going to differentiate into? I mean was I going to grow a foot out of my shoulder or something like that?

Luper tore his rotator cuff 25 years ago during a tubing incident on the Trent River. A subsequent fall during a golf trip in 2015 sent him to a specialist.

I went to see a shoulder surgeon in Richmond. He told me that he didnt think it was a complete tear of my rotator cuff, that I could probably have a minor surgical procedure done and I asked him about stem cell.

After talking with a friend who opted for stem cell treatment for her knee pain, Luper decided to find out more.

My option was if I would have had that shoulder surgery and they had do that bicep tendon repair, I mean I would have been in a sling for six weeks and probably not working for three months.

According to the Food and Drug Administration, stem cells sometimes called the bodys master cells - have the ability to divide and develop into many different cell types. Each new cell has the potential to remain a stem cell or become another type of cell, such as a nerve cell, a skin cell, or a red blood cell. They may also help repair the body by dividing to replenish cells that are damaged by disease, injury or normal wear. Parkinsons disease, spinal cord injuries, damaged organs and cancer could all be possibly treated with the use of stem cells, but more research is needed. Dr. Angelo Tellis is the owner/physician of Aegean Medical, which provides stem cell therapy to patients in Cary, Jacksonville, Morehead City and New Bern.

The adult stem cells we call multipotent stem cells so they can only differentiate into very specific or certain kinds of tissue. Whereas the embryonic stem cells we call pluripotent and can become a variety, almost any tissue. But I only deal with adult stem cells, theyre found to be more useful in clinical applications.

Dr. Tellis says adult stem cells are more responsive to growing tissue in very specific locations. When patients go into Dr. Tellis office for the two hour procedure, he starts by numbing an area of the abdomen and performing liposuction to collect one or two syringes of body fat.

Stem cells can be found in a lot of different tissues throughout the body, but theyre actually in one of the highest concentrations in your own body fat.

The stem cell sample is combined with platelet rich plasma or PRP collected through a blood draw.

That has a lot of the chemical signals and messengers that activate stem cells. So Ill typically combine that with some of the stem cells collected from the body fat and then go under x-ray guidance and put it exactly in the targeted location where we want to create that healing process.

Soreness and stiffness can be expected immediately following the procedure and for about a week after. Dr. Tellis says the results tend to improve with time, taking about three to six months for full recovery. This was Lupers experience in 2016.

Really didnt have to take any pain medications. The joint was really sore over the weekend just because of the injection of the fluid there and after that, I had a small amount of discomfort, but nothing I really had to take medication for.

After three months, Luper says he felt 90 percent better. But he decided to get a second opinion from a shoulder surgeon.

And he told me he thought the stem cells had done a lot but that I still had one little bone spur that was rubbing against the muscle and constantly tearing the little bit of the muscle.

After surgery, Luper says his left shoulder started feeling significantly better in about a month. He was also able to return to one of his favorite pastimes golf. While surgery helped eliminate all of his pain, Luper believes stem cells helped regenerate tissue that was damaged years ago.

He said my rotator cuff muscle didnt even look like it had been torn. I actually tore that, Im sixty now, and I actually tore that when I was 34, 35 tubing on the river and I had to do physical therapy for about three months, but he said he saw absolutely no evidence that Id ever had a rotator cuff tear.

Even though some have found relief and possibly a cure through stem cell therapy, the Food and Drug Administration has not approved any stem cell-based products for use, other than HEMACORD (HE-muh-cord). According to their website, the use of stem cells raises safety concerns such as excessive cell growth, the development of tumors as well as cells migrating from the site of administration and differentiating into inappropriate cell types. And then, theres the cost of the procedure, which is not covered by insurance. The price for the treatment ranges from $2,500 to $5,000. But for those who want to avoid major surgery and the downtime associated with recovery, the risk and cost may be worth it.

If Id have surgery, my deductible would have been that because I have an out-of-pocket max. And I would want to do anything to avoid surgery, especially something that would keep me out of work for three months.

The FDA recommends that consumers interested in stem cell therapy should start a conversation with their doctor about the potential risk to benefit ratio. In addition to Aegean Medical, Advanced Health and Physical Medicine in Greenville and Regenerative Medicine Clinic of Wilmington also provide stem cell therapy in eastern North Carolina.

Read more:
Stem Cell Therapy An Option For ENC Patients - Public Radio East

Read More...

Is Alzheimer’s treatment of injecting stem cells into the brain a breakthrough or quackery? – The Mercury News

March 7th, 2017 6:41 pm

More than eight years after he realized something was wrong, after, as he described it, My brain went

Whats the word? Foggy, Jack Sage finally said after several seconds of silently coaxing his synapses to fire.

More than eight years after his brain went foggy, four years after he was diagnosed with Alzheimers disease and two years since he began an innovative and extremely invasive therapy, Sage said he is being flooded by memories that seem new, or, at the very least, feel easier to retrieve. His daughter, Kate, thought Sage had suddenly begun to open up about his past because he knew his time was growing short.

He should not know who I am at this point, Kate said.

His doctor, Christopher Duma, hopes Jack Sage goes down in history as the one-man turning point in the treatment of Alzheimers disease, while others are skeptical about what Duma has done to Sages brain. Everyone agrees that Alzheimers disease is an exploding problem.

The California Alzheimers Disease Data Report from 2009 projected a 67 percent increase between 2015 and 2030 in residents in Los Angeles, Orange, Riverside and San Bernardino counties living with Alzheimers disease up to 498,137. The same report references a study, between 2000 and 2004, in which 58 percent of the deaths among people 65 and older in California were attributed to Alzheimers disease. New numbers will be released Tuesday.

The Alzheimers Association reported that 610,000 Californians 65 or older had the disease in 2016, and it estimated increases to 690,000 by 2020 and 840,000 by 2025.

On a cool recent night, Sage, a handsome, fit, 82-year-old, sat next to his wife Gloria talking about his children (It is significant that Sage remembers their names James, 46, Kate, 50, and Kelly, 56), recalling when he and Gloria moved into the Newport Beach house with a view of the Pacific Ocean (1990), laughing about their first date at the Bel-Air Country Club (1979), recounting his years as a labor negotiator and executive for Del Monte, Allied Chemical and Continental Airlines (1970s and 60s) and going all the way back to the jack hammering he did in the nickel mines (mid-1950s) in Northern Ontario, Canada.

At this point in his illness, his doctor said he should be having more trouble remembering the perilous tunnels of the Sudbury nickel mine.

You drill into the granite, Sage said. You put dynamite in the rock. You dynamite it. Then you shovel out whats left.

And mining, you might say, is what is happening in Jack Sages brain.

Sages series of recollections, including his exploits on the golf course in Indian Wells where he has a second home and plays several days a week flashbacks representing the three main components of long-term memory: semantic (recalling the meaning of words), episodic (recalling autobiographic milestones) and procedural (recalling how to accomplish tasks) prompted a grin from Duma, the brain surgeon who, for $10,000 per treatment and without insurance coverage, cut a hole in the back of Sages head and injected a stem cell serum that had been sucked out of Sages love handles.

Is this the Alzheimers breakthrough the world has been waiting for? Or, is this unproven medical procedure what University of Minnesota bioethicist Leigh Turner calls quackery and flimflam? Is this an unsafe, money-grab it is being conducted outside the approval process of the Food and Drug Administration preying on the most vulnerable among us?

Turner has written extensively and critically about the Cell Surgical Network (CSN), for which Duma, whose home hospital is Hoag in Newport Beach, is listed as a network physician. The CSN promotes the stem cell revolution, which its literature claims, is an appropriate treatment for people suffering from a variety of inflammatory and degenerative conditions in other words, for cancer, diabetes, bad knees and hips as well as multiple uses in cosmetic surgery.

You dont just start dumping things into peoples brains, Turner said. The problem is people may spend a lot of money and find there is no benefit. He (Duma) is exposing people to serious harm. Fat cells dont belong in peoples brains.

Sage is the first patient in Phase I of a clinical study officially called Intracerebroventricular injection of autologous abdominal fat-derived, non-genetically altered stem cells. Sage was the first Alzheimers patient anywhere to have his own liposuctioned cells injected directly into his brain. He has received eight injections (about two months apart) since November 2014.

Duma quickly offers a qualifier. It is far too early to tell if what he has done to Sage will indeed change the world. He said Sage and, later, 19 other patients have not been harmed by the procedure, and that safety is the only criteria in Phase I. Whether the treatment is effective is a question for Phase II, for which Duma is hoping to attract private funding. Also, he wrote a letter to the national Alzheimers Association asking for $700,000 to continue his work. He was instructed to apply officially later this year. If he gets the grant, the fees for his patients would be waived.

Early in the process, Duma is excited by Sages results.

Sages most recent cognition scores have risen from 45 on the 100-point Memory Performance Index in March 2015 to 54 in September 2015. The volume of his hippocampus the memory center of the brain has grown from the fifth percentile before his first treatment to the 28th percentile after his fourth treatment to the 48th percentile after his eighth treatment.

My golf game is getting better, said Sage, who, heart permitting, plays several times per week. Sages brain isnt his only problem. He has a long history of heart ailments that have required the insertion of 12 stents to keep his arteries open.

You cant make a global conclusion based on one patient, but its a huge turning point, Duma said with the confidence of someone who probes brains for a living.

Duma is somewhat of a maverick in the medical world, a brain surgeon who regularly shuns a scalpel for the gamma knife, a futuristic laser for removing brain tumors. He is known outside the operating room for playing keyboards in bands that specialize in 1970s-era covers of groups such as Genesis, Yes and Emerson, Lake and Palmer. As a child, he was a classmate of John F. Kennedy Jr. at The Browning School in New York City. We called him John John, Duma said.

Duma realizes he will face opposition to his stem cell/brain injection therapy. But, as in all breakthroughs, someone has to be first.

I could have harmed people, he said. I took an enormous leap.

Not much hope

Alzheimers patients dont get better.

They get diagnosed, lose their dignity and die.

The speed at which death occurs is the only variable.

In the depressing world of Alzheimers treatment, Sage and Duma represent equal parts hope and skepticism. The Orange County Register contacted universities and research centers across the country, including Stanford, Harvard, Duke, Florida International, UC Davis, and some of the interview requests were denied while other calls were not returned. Very few medical experts want to talk about the combination of stem cells and Alzheimers disease, apparently because they know so little about it.

An Alzheimers patient improving because of therapy? Im hopeful its true. Im hopeful its true for all patients, said Joshua Grill, the co-director of the Memory Impairments Neurological Disorders (MIND) institute at UC Irvine. We are in dire need.

But, Grill continued, One study does not a revolution make. Ive never read anything about this (Dumas work), and I dont know what science is behind it.

Dean Hartley, Director of Science Initiatives at the Alzheimers Association, knew about Dumas work.

This is new territory, Hartley said. But with one patient, No, you cannot say this is a game-changer.

Hartley said many studies fail at the Phase II level, where more and more people are exposed to the therapy.

Still, Hartley said Dumas work is encouraging.

We want to see things like this happen, Hartley said.

Its not as if Duma is conducting his research in secret. He spoke about his study in public forums twice last year Sept. 28 at the Congress of Neurological Surgeons in San Diego, and Oct. 1 at the International Society for Cellular Therapy in Memphis.

Duma said he is nearly finished writing a paper about his work that he hopes will be published in a peer-reviewed journal.

The stem cell idea

In 1993, Christopher Duma was working at Good Samaritan Hospital in Los Angeles when he and his colleagues began injecting stem cells into the brains of patients with Parkinsons disease. They were making some progress, he said, but politics intervened. Some of the stem cells they were using came from aborted fetuses. Pressure from anti-abortion groups shut that program down.

Fifteen years later, Duma was assisting plastic surgeon Michael Elam on a face-lift on a Parkinsons patient when Elam said, We need to talk about stem cells.

Elam introduced Duma to Drs. Mark Berman and Elliot Lander, the founders of the Cell Surgical Network.

Berman and Lander had been separating stem cells from fat by using a centrifuge (which they own the patent for) and injecting them into knees and hips and other places where injuries had occurred. Their work had passed an Institutional Review Board after 1,524 patients were treated with no adverse effects, Berman said.

If you want to repair an injury, Berman said, the best tissue is the stem cell.

In 2013, Duma suggested a new target for stem cell therapy: the brain.

Duma, with Berman, Lander and Elam as co-authors, tried to begin a study of brain/stem cell injections. But their first attempt at Institutional Review Board approval was denied because they hadnt done animal testing. So they got Dr. Oleg Kopyov at Cal State Northridge to conduct tests on rats.

With the help of Kopyovs work, Duma got Institutional Review Board approval. They chose not to take the usual next step FDA approval.

The Institutional Review Board was expecting us to go through the FDA, Lander said. But there are hundreds of obstructions. The FDA approval process usually takes between eight and 12 years, according to the online journal Medscape.com.

Duma said stem cells present a quandary for the FDA because stem cells are not a drug, and theyre not food. Clinics that take stem cells out of the body and put them back in without additives argue that they are exempt from FDA mandates.

We have been harvesting fat from abdomens and putting them in the brain during brain surgeries since the 1920s, Duma said. We do it nearly on every case for pituitary tumors, acoustic and skull base tumors and for conditions of spinal fluid leakage since the 1920s. If the FDA ruled that harvested autologous fat cannot be used in the brain, then it would change nearly a century of neurosurgical standard of care.

Someday, Duma said he hopes the FDA will recognize his work.

The work cant wait, he said.

The brave one

In August 2013, Jack Sage staggered into the office of Dr. William Shankle in Newport Beach.

Shankle, a renowned expert in cognitive disease he is the author of the Memory Performance Index that is used around the world diagnosed Sage with two problems: Alzheimers disease and hydrocephalus (fluid on the brain). Sage needed a shunt in his brain to drain the fluid and relieve the pressure.

So Shankle walked him down the hall (their offices are yards apart on the same floor in the same building) and introduced Sage to Christopher Duma, medical director of Hoag Hospitals Brain Tumor Program, and the surgeon who would put in the shunt.

Duma remembers that first meeting. Sage was in straight-line cognitive decline, Duma said.

Shankle would not grant an interview about Duma or his treatment. Shankle said he is wary of hocus pocus about Alzheimers disease without saying that Duma has done anything wrong. More than a decade ago, Shankle tried a surgical stem cell therapy on patients. He removed patients stem-cell-rich omentum, a fatty sheath covering the abdomen, cut open their skulls and stretched the omentum directly on their brain. Four of the six patients he studied had serious complications from the surgery.

The patients improved in cognitive tests, but the surgery was too much for them.

The method of delivering the treatment was radical (surgical transposition of the greater omentum to the surface of the brain while keeping the blood supply intact), Shankle wrote in an email. After showing that it really works, my goal was to never do the surgery again but find a different way of delivering these critical factors less invasively.

Sage was the patient Duma had been waiting for.

Jack was a man who was doomed, Duma said. He looked like classic Alzheimers. He had no ability to follow a train of thought. He was asking and re-asking the same questions. People like Jack are there, but theyre not there.

Sage was perfect for Duma for other reasons. He has always been a fitness nut cycling, tennis, golf, skiing and 10K runs were all part of his lifestyle. Kate Sage said he has been ordering salmon and spinach for dinner at restaurants for years.

Jack is the experimental model, Duma said. He is the brave one.

During two years of treatments, Sage has either maintained or slightly improved his cognitive health. He had a major heart attack in 2016, making his brain less of a cause for concern than his heart.

Kate said she doesnt know if Dumas treatment is working.

Its hard for me to say this is miraculous, Kate said.

She said she doesnt worry about his brain as much anymore.

Hes going to drop dead with some kind of a heart thing, she said. Hes not going to lose his memory.

Jack Sage

The tragedy of Alzheimers disease is that it not only steals the history that makes us who we are. It takes our skills, our beliefs, our independence, our ability to love.

So far, Jack Sage is still Jack Sage. Obviously, he doesnt know if he would be the same without Dumas treatments.

I can tell Im getting better and better, Sage said. Is that pure optimism? The Placebo Effect?

In January, Jack Sages drivers license came up for renewal. He said hes able to remember driving directions without problem. He still navigates the route from his home in Newport Beach to his other home in Indian Wells. But, he was required to pass the written test, and Sage feared he wouldnt be able to remember the complex rules of the road.

I was worried, he said.

But he passed, and his license was extended five years.

His improved memory, he said, sometimes catches him by surprise.

These memories come up when I dont even think about it, Sage said.

Sometimes, the memories take Sage places he doesnt want to go.

When he worked in the nickel mines in the 1950s, he and his first wife had a son.

His name was Mark, Sage said, speaking slowly as if the memory was bubbling up from depths he didnt want to consider. We rented a house with a playroom. My wife went shopping, and I was upstairs

I was working on my school work for McMaster University

Mark fell

we had a drainage basin inside the house

when I got to him, he was gone

Sage stopped talking as if flooded by new emotions over the death of his son.

We were distraught, he said. It was tough times for years.

In the murky world of Alzheimers therapy, Jack Sage is still mining.

Contact the writer: ksharon@scng.com

Go here to read the rest:
Is Alzheimer's treatment of injecting stem cells into the brain a breakthrough or quackery? - The Mercury News

Read More...

Trump’s blindness on trade is all too easy to see – Washington Post

March 6th, 2017 7:41 am

PRESIDENT TRUMPS international economic team is still a work in progress, though based on two early top nominations Robert Lighthizer as U.S. trade representative and Peter Navarro to head a new National Trade Council he fully intends to keep the protectionist promises of the campaign trail. Certainly a newly released administration document, The Presidents 2017 Trade Policy Agenda, reflects the influence of Mr.Lighthizer and Mr. Navarro. The six-page statement rehearses once again their critique of U.S. trade policy since the Cold Wars end: Multilateral trade agreements and institutions such as the North American Free Trade Agreement and World Trade Organization have sacrificed American sovereignty, to the ultimate cost of U.S. jobs, especially manufacturing jobs.

Familiar and, indeed, shared by many of Mr.Trumps Democratic opponents though it may be, this narrative is far from an accurate diagnosis. It is true, as the new Trump agenda notes, that manufacturing employment declined, in absolute numbers, between 2000 (the last year before the United States approved Chinas entry to the WTO) and 2016, from 17.2 million to 12.3 million. Whether this decline is 100 percent the fault of the WTO, NAFTA or any other multilateral trade deal, as opposed to automation and other long-term factors not unique to the United States, is another question.

As a new analysis by economic historian Bradford DeLong of the University of California at Berkeley shows, the past two decades of job losses in manufacturing are part of a trend that began after the Korean War. Factory work went from 32 percent of non-farm employment in 1953 to 16 percent in 1990: long before NAFTA or China. For comparisons sake, Mr. DeLong notes that Germany held out by many U.S. trade critics as a paragon of manufacturing employment preservation shed half of its factory jobs between 1970 and 2015.

Obviously, these numbers dont salve the pain, material and psychic, of those who lost out from these sweeping historical processes. They do, however, suggest theres little to be gained by trying to renegotiate existing trade institutions, or to opt out of them selectively, when, say, a WTO ruling does not comport with U.S. interests as the new Trump agenda suggests. To the contrary, DeLong calculates that Chinas accession to the WTO and NAFTA combined cost the U.S. 500,000 net manufacturing jobs, in a workforce of more than 150 million people.

Again, we dont dispute the impact especially on the light industries such as shoes or furniture hardest hit by imports. Nor do we quarrel with the Trump agendas assertion that trade with China has largely failed to induce greater abiding of the law and transparency by that one-party state. Yet the best way to counteract Chinas mercantilism would seem to be by precisely the sort of U.S.-led multilateral cooperation that the Trump administration has rejected, in the form of the Trans-Pacific Partnership. The Trump agenda blames past policymakers for turn[ing] a blind eye to unfair trade practices in the pursuit of putative geopolitical advantage. Geopolitics, though, is just another word for shaping the world to serve all U.S. interests, with a minimum of conflict. And the real blindness consists in unilaterally asserting sovereignty and protection without regard to the legitimate interests of other nations, or their capacity for retaliation.

See the article here:
Trump's blindness on trade is all too easy to see - Washington Post

Read More...

Maine woman faces blindness with a sense of determination – Press Herald

March 6th, 2017 7:41 am

Julie Voisine clutches the red-and-white cane in her hand and listens to the Congress Street traffic whiz past her.

Can you get us back to the car? Mike Dionne asks.

Probably not, Voisine replies.

Break it down, Dionne says. You got it.

Says the man who can see, Voisine says.

She gives him a sarcastic smirk, but she starts to walk.

Now 53, Voisine has been legally blind since age 28. She has retinitis pigmentosa, an inherited eye disease that has slowly claimed her peripheral vision. She also has developed macular degeneration, which is causing her to lose her central vision. Although her sight has always been limited, it has shrunk to a pinprick in recent years.

I have one spot in my vision, Voisine said. Its like taking a straw and putting it up to your eye and looking out of it and crimping the end of it.

In January, Voisine enrolled at the Iris Network Rehabilitation Center in Portland. The 12-week residential program teaches skills she will need to live and work independently when she has entirely lost her vision. Dionne, an orientation and mobility specialist, is one of the instructors who has been working with her for weeks.

Earlier in the week, Voisine slipped on a patch of ice during a solo trip to the post office. Her arm is in a sling during her lesson with Dionne on a sunny Thursday in February, but she sets out with her cane anyway.

Theres too many other things trying to stop me, Voisine said. My vision isnt going to be one of them.

BOOT CAMP FOR THE BLIND

The Maine Institution for the Blind formed in 1905. Its founder was a visually impaired traveling almanac salesman who wanted to help other people with vision loss earn a living wage and learn a trade. The nonprofit has changed its name over the years, but Director of Program Services Rabih Dow said the Iris Network still has the same goal.

People come to us and say, What jobs can blind people do? Dow said. We say, What job would you like to do?

The 2015 National Health Interview Survey estimated that 23.7 million American adults about 10 percent of Americans 18 years and older reported they have some level of vision impairment. That group includes a range, from people who have trouble seeing even while wearing contacts or glasses to those who are completely blind. Most are born with sight and lose it either through disease or trauma, Dow said.

The stereotype of blindness is very stark, he said. It is a relatively uncommon disability, so it can be very isolating.

In 2015, the Iris Network added its first live-in program. Over three months, clients live in a dorm setting in Portlands Parkside neighborhood and study a range of subjects.

Think of it as a boot camp for the blind, Dow said.

Growing up in Penobscot County, Voisine has always known she would lose her vision. Many of her family members her mother, six of her eight siblings, her son also have retinis pigmentosa.

As an adult, she ran several small businesses over the years with her husband. Before he died nine years ago, they had owned a garage, a redemption center and a karaoke service together. But as her vision has worsened, Voisine has not been able to work at all.

Limited public transportation near her home in rural Kingman has frustrated her. She likes to travel, but she relies on her friends to drive her to appointments and the grocery store. She loves to bake, but she began burning or cutting her hands in the kitchen. She missed reading, but she abandoned two attempts to learn Braille.

When a counselor told her about the Iris Network Rehabilitation Center, Voisine signed up immediately.

This program for me is about freedom, she said. Its being free to do the things I want to do.

LEARNING TRICKS OF INDEPENDENCE

Voisine bends over a list of ingredients with her magnifying glass.

In a practice apartment at the Iris Network, clients learn how to cook, do laundry and manage their homes without their vision. So far, Voisine has made red velvet truffles and cheesecake in the test kitchen. Today, she considers two copies of the same recipe for chocolate chip cookies one in large print, one in Braille.

I had to give away a lot of my recipe books before I came here, she said.

With her arm in a sling, Voisine needs some help whisking from Karen McKenna, a certified vision rehabilitation therapist. But she still finds the butter in the refrigerator and preheats the oven. McKenna has labeled many of the spices and measuring cups in the kitchen with Braille.

She and Voisine review the tips she has learned in the kitchen. They place all the necessary ingredients on a tray to keep them organized. Voisine knows to feel the edges of the broken eggshell with a finger to identify the size and shape of any missing chunks. McKenna teaches her students how to identify the sounds and smells that mean food is done cooking.

Hey, Siri, set a timer for nine minutes, Voisine instructs her phone.

The practice apartment is just one of the classrooms that Voisine visits each week.

Elsewhere, she is finally getting the hang of Braille. In the low-vision clinic, clients learn how to maximize the sight they still have. For Voisine, this involves tools like glasses to reduce glare and talking apps on her cellphone. The program puts an emphasis on learning to use the computer to pay bills, file taxes, keep up with an address book and manage other daily tasks. All clients participate in individual and peer counseling. Voisine is making a toy workbench for her grandson in a woodworking class. Her orientation and mobility class takes her outside in all weather to find her way through the grocery store, the public bus system and the streets of Portland.

I am not my cane, Voisine said. I am just somebody trying to live my life.

The smell of warm cookies fills the kitchen. Voisine sniffs the air.

The cookies are almost done, she says.

She opens the oven just as the timer buzzes.

FROM CAUTIOUS TO CONFIDENT

When Voisine graduates from the Iris Network program, she hopes to find work in Portland.

She has joined the YMCA and applied for an apartment. She often helps the staff at the nursing home where her mother lives, so she has decided to become a certified nursing assistant. She would also like to find a part-time job at a bakery.

She will take the bus from Portland to New York City to visit her son this spring, and she wants to travel to England and Ireland next year.

Ive had people say to me, Id rather be dead than blind, she said. Im like, Im sorry your life is so small.

When she first started to walk the streets of Portland with Dionne, Voisine was cautious and slow. She often wears a blindfold during these lessons to prepare for her total vision loss, and the traffic in Portland is busier than her hometown. But her confidence has grown with every lesson.

Shes embraced it, Dionne said. She goes out and does the things she wants.

During their recent lesson, she walks Congress Street in the afternoon sun. Dionne follows a few paces behind, ready to intervene when she gets turned around in a parking lot. He tells her to listen to the traffic and guess the configurations of the intersections they pass.

Its a two-way, she says confidently at the intersection of Pearl and Congress streets. Its a light.

Voisine pauses at the intersection of Congress and Exchange streets. This is the final crosswalk of her lesson. The car is just a block away.

After we cross here, youre going to turn left, Dionne said.

Voisine nods her head vigorously.

She starts to step into the street, but immediately jumps back onto the curb as she hears a car approach. The white PT Cruiser makes the turn onto Exchange Street.

A group of teenage girls with Urban Outfitter shopping bags chatter to each other as they cross the street. Voisine reaches a foot onto the asphalt, then pulls it back. She tilts her head and listens to the sounds of passing cars. And then, Voisine quickly steps into the road and strides across. She cant see the white lines of the crosswalk, but she follows them perfectly. She sweeps her cane in a wide arc in her path, and Dionne hurries behind her to keep up with her quick steps.

Her cane taps the opposite curb, and she turns left.

Megan Doyle can be contacted at 791-6327 or at:

[emailprotected]

Twitter: megan_e_doyle

Read the original:
Maine woman faces blindness with a sense of determination - Press Herald

Read More...

WATCH: Helping farmers through agricultural biotechnology – Rappler – Rappler

March 6th, 2017 7:41 am

The UP Genetic Researchers and Agricultural Innovators Society strives to uphold awareness on the ways, means, and science behind agricultural biotechnology to help students and farmers alike

Published 6:59 AM, March 06, 2017

Updated 9:19 AM, March 06, 2017

MANILA, Philippines How can agricultural biotechnology help and serve farmers and students alike?

These students from the University of the Philippines Genetic Researchers and Agricultural Innovators Society or UP GRAINS found a way.

We think its important to promote biotechnology because its one of the most advanced fields of science and we think it is also neglected in the Philippines," founding Vice-President of UP Grains Kohlin Lallaban said.

UP GRAINS, which was formed in 2014 in UP Los Baos, is an academic organization that promotes agricultural biotechnology. The group helps farmers make a living. Its programs allow students from Batangas, Laguna, and Camarines Norte provinces learn about techniques in biotechnology and how they can apply these to their research.

They bring experts and professors from different universities in Laguna and Batangas to communities, teaching farmers how to grow their crops better.

The student organization has touched lives through its programs which include academic tutorials (Chem 40: Basic Organic Chemistry Tutorials), educational discussions (AgriBioTalk Series), inter-high school information drives (Lakbay-Bioteknolohiya Workshops), farmer-oriented extension programs (Ugnayan Series), interactive advocacy campaigns (#EveryButilCounts, Free Demo Shirt Printings), and even a nationwide junior research conference (Project BT).

There was this one time that we did an extension activity in Laguna. We pushed the farmers to establish an irrigation system for their farm. Right now, theyre producing almost 40% more of cavans of rice than they were able to produce before, Lallaban shared.

One of the greatest ironies in the Philippines is that food producers like farmers and fishermen are the most vulnerable to hunger. UP GRAINS wants to change this situation in rural communities. By change, they mean continuous innovation for a better future, according to Lallaban.

"We think that the biggest lesson that our organization learned from our immersions is that there are bigger things than us, there are bigger things that we have to do, there are bigger things that we have to think about and that there is no better time to do that than now." Rappler.com

UP GRAINS is a partner organization of Rappler's civic engagement arm MovePH. For more information on how you can help or be part of UP GRAINS, check out their stories on X. Know more about our other organization partners:

Do you want your organization to be part of MovePH's X Network? Email us at move.ph@rappler.com!

At Rappler, we believe there are many freedoms: to speak, to choose, to love, or just to be. #InspireCourage is our campaign to encourage people to speak up, engage in issues, and continue fighting for the change they want to see. Be part of the conversation

Go here to read the rest:
WATCH: Helping farmers through agricultural biotechnology - Rappler - Rappler

Read More...

Sex, Gene Editing, And Electronic Dance Music: How To Teach Entrepreneurship In Biotechnology Part 1 – Forbes

March 6th, 2017 7:41 am

Forbes
Sex, Gene Editing, And Electronic Dance Music: How To Teach Entrepreneurship In Biotechnology Part 1
Forbes
I assigned the readings for session 7 via class emails after sessions 4 and 5, disguised as the reading for sessions 5 and 6. First up: Trials, Amy Dockser Marcus' series on how a group of parents of children with Niemann-Pick type C disease tried to ...

See the rest here:
Sex, Gene Editing, And Electronic Dance Music: How To Teach Entrepreneurship In Biotechnology Part 1 - Forbes

Read More...

RBC Capital Mkts Released Sector Perform Rating on Puma Biotechnology Inc (PBYI) – Times Money

March 6th, 2017 7:41 am

Puma Biotechnology Inc (PBYI) was Reiterated by RBC Capital Mkts to Sector Perform while Lowering the Price Target of the company shares to $ 17 from a previous price target of $48 . RBC Capital Mkts advised their Clients and Investors in a research report released on Mar 2, 2017.

Based on several research reports , Shares were Reiterated by RBC Capital Mkts on Mar 2, 2017 to Sector Perform and Lowered the Price Target to $ 17 from a previous price target of $48 .

Several company insiders have filed Insider transactions , on Jan 24, 2017, Steven Lo (Chief Commercial Officer) sold 2,290 shares at $33.24 per share price. According to the SEC, on Jan 24, 2017, Charles R Eyler (officer ) sold 820 shares at $33.24 per share price. On Jan 24, 2017, Richard Paul Bryce (SR VP, CLINICAL RESEARCH & DEV) sold 2,293 shares at $33.24 per share price, according to the Form-4 filing with the securities and exchange commission.

Puma Biotechnology Inc opened for trading at $36.2 and hit $37.6 on the upside on Monday, eventually ending the session at $37.35, with a gain of 3.18% or 1.15 points. The heightened volatility saw the trading volume jump to 9,22,483 shares. Company has a market cap of $1,375 M.

Puma Biotechnology Inc. is a biopharmaceutical company that focuses on the acquisition development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive breast cancer and patients with non-small cell lung cancer breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors HER1 HER2 and HER4.

See more here:
RBC Capital Mkts Released Sector Perform Rating on Puma Biotechnology Inc (PBYI) - Times Money

Read More...

Research gaps persist in psoriasis, psoriatic arthritis – ModernMedicine

March 6th, 2017 7:41 am

Orlando The advent of increasingly effective and still costly biologic drugs for psoriasis and psoriatic arthritis (PsA) has highlighted the fact that dermatologists do not know which patients would benefit most from preventative measures.

A key unanswered question in psoriasis is whether physicians can predict and therefore prevent progression to PsA, said Mark Lebwohl, M.D. He is Sol and Clara Kest Professor and Chairman, Department of Dermatology, Icahn School of Medicine at Mount Sinai.

Before biologics, "The drugs that we had helped the pain of arthritis but were not dramatically effective at preventing joint destruction. Methotrexate is a classic example patients still benefit from it today, but the joints continue to deteriorate as evidenced by x-rays."

Tumor necrosis factor (TNF) alpha inhibitors were the first drug class allowed to claim that they prevent radiographic progression of PsA. "Etanercept was the first, followed by infliximab and adalimumab. Then came golimumab and certolizumab. These 5 drugs are dramatically effective for psoriatic arthritis they don't just get rid of the pain, but they also prevent x-ray progression."

More recently, the interleukin (IL) 17 blockers secukinumab and ixekizumab have shown similar abilities. "We have quite a few tools now to prevent joint damage. If we knew in advance which patients with psoriasis were going to develop psoriatic arthritis, it would help us help our patients. We could put them on those drugs early to prevent joint damage."

Among patients with psoriasis and PsA, he said, 72% present with psoriasis first. MRIs can show bone marrow edema (a sign of impending joint damage), "But we need better tests to predict which patients will get psoriatic arthritis." To that end, said Dr. Lebwohl, several companies are investigating genetic markers, while physicians continue to explore use of imaging modalities. "A genetic or serologic marker would be most helpful."

Similarly, researchers are attempting to predict which patients will develop other comorbidities such as cardiovascular disease. "When the biologics came out, patients were put into registries. And we've been finding, particularly with the TNF blockers, that there's a dramatic reduction in heart attacks in people who take these drugs."

A third knowledge gap, Dr. Lebwohl said, is which patients will respond to which treatments. "The new treatments that are coming out are dramatically effective in almost everybody. The problem is, they all cost a fortune." Knowing which patients would likely respond best and which ones would do just as well with cheaper treatments will help dermatologists and their patients immensely, he said.

Disclosures: Dr. Lebwohl has been a clinical investigator for most manufacturers of drugs for psoriasis and psoriatic arthritis. All payments from these companies go not to him but to Mount Sinai.

Visit link:
Research gaps persist in psoriasis, psoriatic arthritis - ModernMedicine

Read More...

Blissful color-blindness of the young children … – Enid News & Eagle

March 5th, 2017 4:42 pm

Recently the mother of a 5-year-old boy in Louisville, Ky., told her young son he needed a haircut.

He asked if he could get the same haircut as his best friend, because Were going to trick the teacher.

The boy thought if he had the same haircut as his buddy, their pre-K teacher couldnt tell them apart.

Jax, the boy needing the haircut, wanted to get a buzz cut like his friend, Reddy, who is also 5. So he did.

The punchline of this endearing story is that Jax is white, Reddy is black. The difference in their pigment, apparently, never crossed the boys minds when they plotted to fool their teacher.

Would that we all could be that way, seeing each other as friends and fellow human beings rather than as black, white, yellow, red, brown, green, purple or any shade.

Children see only another person whom they like and want to play with, not a person of another race. Prejudice, it seems, comes only with age and experience.

In the classic Rogers and Hammerstein musical South Pacific, there is a song in the second act that highlights this phenomenon.

Young Navy Lt. Cable has fallen in love with a Polynesian girl, Liat, but he knows he cannot marry her because of his familys prejudice.

At the same time, Ensign Nelly Forbush decides she can no longer love French plantation owner Emile because of his two half Polynesian children.

It is a short song with a powerful message, Youve got to be taught to hate and fear.Youve got to be taught from year to year. Its got to be drummed in your dear little ear. Youve got to be carefully taught.Youve got to be taught to be afraid, of people whose eyes are oddly made, and people whose skin is a diffrent shade.Youve got to be carefully taught.Youve got to be taught before its too late, before you are 6 or 7 or 8, to hate all the people your relatives hate, youve got to be carefully taught!

Over the years too many have learned those lessons too well.

In an article published in the St. Louis American, an African-American newspaper in that Missouri city, Roland Bob Harris, a St. Louis native, writes about his time in the Air Force, including his tenure serving at Vance Air Force Base in the late 1950s.

Segregation reigned supreme, Harris wrote. The blacks in Enid literally lived on the other side of the tracks. There were only two black policemen. They could only patrol in the black section of Enid. Enid was a very dismal assignment.

Thank God we have come a long way since the late 1950s, though we still have far to go.

For young airmen assigned to Vance today, this still may be a dismal assignment, but only because of Enids small size and long distance from a major metropolitan area, not because of rampant racism.

We could learn a lot from Jax and Reddy. Color shouldnt matter, period. Of course, neither should your country of origin, how you choose to worship nor who you decide to love.

Why must we be so quick to hate, so eager to distrust, so reluctant to love, so hesitant to accept?

We have, I fear, been carefully taught.

We can only pray thats a lesson Jax and Reddy never learn.

Mullin is senior writer of the News & Eagle. Email him at jmullin@enidnews.com or call 548-8145.

More here:
Blissful color-blindness of the young children ... - Enid News & Eagle

Read More...

Why Puma Biotechnology Inc. Got Hammered Today – Motley Fool

March 5th, 2017 4:41 pm

What happened

Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed "Aphinity."

Image source: Getty Images.

In Roche's trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy, and then took Perjeta and Herceptin, or just Herceptin, for an additional year. Roche didn't release the full data from the clinical trial, but it did say the triple combination reduced the risk of recurrence of invasive disease or death compared to Herceptin and chemotherapy alone.

The potential to establish a new standard of care where patients take Herceptin and Perjeta for a year could be problematic for Puma Biotechnology because its drug candidate, neratinib, was tested after just Herceptin use, the current standard of care.

Without any data, doctors will likely wonder whether neratinib helps patients that have received Herceptin and Perjeta. And the relapse rate for patients on the current standard of care is already quite low; if adding Perjeta decreases it further, doctors and their patients may decide taking another drug after that isn't worth it, especially given neratinib's side-effect profile.

Investors will have to wait for the full data from Aphinity -- perhaps at the American Society of Clinical Oncology meeting in June -- to know how much better Herceptin plus Perjeta is than Herceptin alone, and how that might affect neratinib's sales, assuming it's approved later this year.

Brian Orelliand The Motley Fool have no positions in any of the stocks mentioned. The Motley Fool has adisclosure policy.

Link:
Why Puma Biotechnology Inc. Got Hammered Today - Motley Fool

Read More...

Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead … – Business Wire (press release)

March 5th, 2017 4:41 pm

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE) today announced that Richard L. Wang, Ph.D. will be appointed Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd, the companys 50/50 owned joint venture in China with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH,02196.HK).The companies announced the formation of the joint venture in early 2017 to develop, manufacture and commercialize autologous T-cell therapies to treat cancer in China, including Kites lead cell therapy product candidate, axicabtagene ciloleucel. Final registration of the joint venture is ongoing.

We are on the cusp of significant change with CAR-T therapy as a treatment for serious blood cancers, said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. This type of revolutionary change requires deft management, a deep understanding of country-specific requirements, and the ability to unite the strengths of partners, collaborators and the local medical community. Together with Fosun Pharma, we believe Dr. Wang has the unique experience essential for the success of Fosun Kite Biotechnology, CAR-T therapy and axicabtagene ciloleucel in China.

Dr. Wang has extensive experience in the biopharmaceutical industry including US and China based leadership roles at Procter & Gamble, Bristol-Myers Squibb, AstraZeneca and GlaxoSmithKline. He most recently served as Chief Operating Officer of Cellular Biomedicine Group, a U.S. listed clinical-stage immuno-oncology and cell therapy company with operations in China. Previously, Dr. Wang was Senior Site Leader and Head of Operations for GlaxoSmithKline research and development in Shanghai. He obtained a B.S. degree in Cell Biology from the University of Science & Technology of China, a Ph.D. degree in Molecular Biology from the University of Maryland, Baltimore, and a M.B.A. degree from Xavier University in Cincinnati.

Under Dr. Wangs leadership, the joint venture will establish business operations in Shanghai and build a senior leadership team to oversee technical operations and clinical development activities.

AboutKite

Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Kite is based inSanta Monica, CA.For more information onKite, please visit http://www.kitepharma.com. Sign up to follow @KitePharma on Twitter at http://www.twitter.com/kitepharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to complete the joint venture registration, the ability of CAR-T therapy to invoke significant change in the treatment for serious blood cancers, and the success of Fosun Kite Biotechnology, CAR-T therapy and axicabtagene ciloleucel in China. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-K for the year ended December 31, 2016. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Kite assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Visit link:
Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead ... - Business Wire (press release)

Read More...

Thursday’s Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI) – Smarter Analyst

March 5th, 2017 4:41 pm

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares skyrocketed over 65% this morning, after the drug maker announced top-line results from its AURA-LV Phase IIb study with voclosporin (VCS) in patients with lupus nephritis (LN) that showed at 48 weeks, the study met its complete remission (CR) and partial remission (PR) endpoints.

FBR analyst Vernon T. Bernardino commented, We are impressed with the results, as CRs and PRs at 48 weeks exceeded CRs and PRs at 24 weeks, with one exception. As a reminder, each study arm included standard of care mycophenolate mofetil (MMF) as background therapy and a forced steroid taper. There were no unexpected safety signals or deaths observed in VCS-treated patients. Thus, in addition to strong efficacy, VCS appears to allow safe steroid sparing. We think the results are robust and bode well for a successful Phase III trial, which could make VCS the first approved therapy for LN.

As of this writing,the 4 analysts polled by TipRanks (in the past 6months) rate Aurinia stock a Buy. With a return potential of 39%, the stocks consensus target price stands at $8.50.

Puma Biotechnology Inc (NASDAQ:PBYI) shares lost one-quarter of their value today, after competitor Roche announced positive top-line results from the highly anticipated APHINITY trial,which explores usefulness of Perjeta in adjuvant breast cancer. Recall, Puma has US/EU regulatory applications under review for neratinib in the extended adjuvant setting based on positive Phase 3 ExteNET data.

J.P Morgan Cory Kasimov commented, Todays PR is expectedly light on details, so well have to wait for ASCO to get the full picture. In our view, the future of neratinib in this indication largely rests on the nuances of the data, namely: 1) the magnitude of benefit, 2) the subgroups that drive this benefit (HR+ and/or HR-), and 3) details of the safety profile. The ultimate impact on Puma remains to be seen, but this outcome has obviously taken the near-term best-case scenario off the table. Our prevailing expectation was that on positive APHINITY results, PBYI shares could initially lose roughly 1/3 of their value. That said, investor feedback weve been getting has suggested that this potential dip could provide an opportunity ahead of the ASCO details as well as a number of pending neratinib data points in 1H17.

Out of the 8 analysts polled by TipRanks (in the past 12 months), 6 rate Puma Biotechnology stock a Buy, while 2 rate the stock a Hold. With a return potential of 180%, the stocks consensus target price stands at $79.

Go here to see the original:
Thursday's Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI) - Smarter Analyst

Read More...

CBDual Biotechnology Corp. Announces the Completion of their … – Yahoo Finance

March 5th, 2017 4:41 pm

LOS ANGELES, CA / ACCESSWIRE / March 2, 2017 / CBDual Biotechnology Corp. ("CBDUAL") announced today the completion of the company's new clinical trial center in Southern California.

CBDual's new facility provides patients with easy access to participate in clinical trials of new medical cannabis medications, therapies, and products. CBDual will develop protocols to improve patient safety and data integrity in clinical research trials in compliance with the HIPAA.

The first scheduled trial will study the medicinal and therapeutic effects of CBD on oral health. The study anticipates between 1,000-2,000 patients and will test the effects of different CBD based mouthwashes and toothpastes.

CBDual has recently entered into a cross licensing agreement with Cavitation Technologies, Inc (OTCQB: CVAT; Berlin: WTC). This agreement covers intellectual property involving the application of technology and patented processes to produce high quality pharmaceutical grade cannabis materials with increased bio-availability and increased shelf life.

Dr. Greg Rubin, CEO of CBDual Biotechnology Corp., previously commented, "The improvement of consumer and medical products require the development of the best quality and utilization of the most innovative technologies in order to achieve ultimate results. The impact of the new clinical research brings us one step closer to introducing our new products to the US markets."

Recent breakthroughs in Cannabinoid (CBD) therapies and orally administered products prompt strong forecast for 2017. The Hemp Business Journal estimated that the CBD market will emerge as a $2.1 billion market in consumer sales by 2020. That represents a 700% increase from 2016. According to the National Institute on Drug Abuse, a number of studies have shown that CBD is a non-psychoactive cannabinoid and has a wide range of medical benefits, such as anti- inflammatory and anti-oxidant and many other health related benefits.

About CBDual Biotechnology Corp

CBDual Biotechnology is a privately held; US based Biotechnology Company with a proprietary technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes good gums health and overall dental health due to higher effectiveness of the delivery methodology. Company was founded in 2016 and is headquartered in California with its R&D capability in Israel and Ukraine..

Website: http://www.cbdual.com/

About Cavitation Technologies, Inc.

Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement, water treatment and cannabidiol processing. As an add-on to its existing neutralization systems, the company's patented Nano Reactor allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield.

Website: http://www.ctinanotech.com/ Follow us on Twitter: https://twitter.com/ctinanotech Like us on Facebook: https://www.facebook.com/ctinanotech

Forward Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder's value. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Read More

Cavitation Technologies, Inc.

Contact:

Investor Relations Jessica Steidinger Jessica@ctinanotech.com Phone (818) 718-0905

SOURCE: CBDual Biotechnology Corp.

See more here:
CBDual Biotechnology Corp. Announces the Completion of their ... - Yahoo Finance

Read More...

Jonathan Allen unconcerned about shoulder arthritis – NFL.com

March 5th, 2017 4:41 pm

INDIANAPOLIS -- If the arthritis in Jonathan Allen's surgically repaired shoulders becomes a problem for him during his NFL career, it will have already been an awfully long one.

The former Alabama star said Saturday that doctors have told him the condition shouldn't affect him for 15-20 years, according to the doctors he spoke with.

"The shoulder feels good. Every doctor said if there's a problem, it's after football, way after football. I have no concerns with it at all," Allen said at the NFL Scouting Combine. "... They said I have some arthritis in my left shoulder. It's not really a problem now, but it might be a problem 15, 20 years down the road so I'm not worried about that right now. I'm worried about playing good for whichever team I go to."

NFL Media Insider Ian Rapoport reported Thursday that Allen has mild arthritis in both shoulders.

It certainly never showed up on the field at the college level. Allen was a durable anchor on Alabama's vaunted defensive line for more than two years as a starter. He piled up 22.5 sacks over his last two years in college, playing in all 30 Crimson Tide games over that stretch. With the versatility to play multiple positions along the defensive front, and an ability to defend the run to go with his pass rush skills, Allen is considered one of the elite prospects in the draft.

He repped 225 pounds 21 times on the bench press for NFL scouts Saturday, and said he's feeling fine physically.

"I have no restrictions on anything I do. Like I said I feel good. It's probably the best I've felt in the last four years. I feel good, refreshed, re-charged, ready to go," Allen said.

NFL Network draft expert Mike Mayock ranked Allen as the No. 1 interior defensive lineman in the draft entering the combine.

Follow Chase Goodbread on Twitter @ChaseGoodbread.

Go here to see the original:
Jonathan Allen unconcerned about shoulder arthritis - NFL.com

Read More...

Fashion for People with Arthritis and Other Painful Conditions – Healthline

March 5th, 2017 4:41 pm

Fashion designer Michael Kuluva hasnt let rheumatoid arthritis (RA) get in his way.

But hes acknowledged a notable void in the fashion and beauty industries when it comes to adaptive options and more inclusive designs for people living with an illness or disability.

He isnt alone.

There are online initiatives in the form of hashtags, blogs, Twitter chats, and Instagram accounts that explore the relationship between fashion and chronic illness. It can be a pain for people in pain to dress themselves.

It can also be difficult to find fashionable, stylish options that are also adaptive and functional for anyone with a disability or aching body.

Read more: Get the facts on rheumatoid arthritis

Kuluva is the founder of the label Tumbler and Tipsy, which he debuted at New York Fashion Week.

However, the former figure skater didnt always dream of a career in fashion.

After he retired from his sport in his mid-20s, Kuluva realized that he had another interest and a talent that couldnt be ignored.

He began working as an assistant for a designer despite having no formal training. He eventually secured a scholarship to the Fashion Institute of Design and Merchandising (FIDM).

During his time at FIDM, he found that he was performing well academically but couldnt perform some basic tasks.

I noticed I could not even draw a straight line, and I had other little setbacks. I had trouble cutting fabric and I began comparing myself to other students, Kuluva told Healthline. My joints just weren't doing what they should be. I had pain. Then, one day, walking from class to my car, my back suddenly gave out.

Kuluva first thought he had a kidney stone. He saw a urologist who told him the issue wasnt urological and suggested that Kuluva see a rheumatologist.

After visiting three doctors and waiting months to be seen at the Mayo Clinic, Kuluva was eventually diagnosed with RA. Through trial and error, he found a combination of medications that worked pretty well for controlling his condition.

No medication is ever 100 percent, but my regimen is going well, he said. If I miss a few weeks of treatment, because of travel or fashion shows for example, then I can definitely feel that. I didnt really have issues while figure skating. I had some bursitis, but I dont think it had anything to do with my RA. So, my decision to retire from skating was not related to my rheumatoid arthritis, but Im glad I retired when I did.

Read more: The making of an American Ninja Warrior

After showing a collection that would eventually help to launch the career of model Kendall Jenner, Kuluva started to think about how he could use his art and his platform for good.

Theres been a lot of proud moments a lot of great moments that are unforgettable. Kendall Jenner helped to launch my career and vice versa, he said. This gave me kind of a voice in society. So my CreakyJoints collection was a pivotal moment where I got to express myself within my fashion.

The collection is a collaboration with the arthritis-related nonprofit CreakyJoints, to promote RA awareness on the runway.

CreakyJoints has worked with celebrities like actress Megan Park to promote RA awareness, but this fashion collection came about rather organically.

Real Housewife of New York Jill Zarins daughter was backstage in my dressing room, and we got to talking because she has a form of arthritis, too. It got me thinking, and after our conversation I figured I might contact CreakyJoints after that collection was done, Kuluva recalled.

He said he just wanted to lend his voice to a cause and be an advocate for something.

I like the nonprofit mindset of CreakyJoints, all for the patients. The president, Seth, has [spondyloarthritis], and so he really gets it, Kuluva said. So we all had lunch and brainstormed what we could do together. They pretty much left it up to me. I came up with putting starbursts on all the joints in my SS2017 show. The starbursts, while fashionable, represent the joint pain.

Kuluva said the fashion industry still has a void to fill with adaptive and inclusive fashions for people who are sick or have disabilities. This is especially in terms of shoes and footwear.

Kuluva did acknowledge that some current trends of more comfortable and functional styles may be ideal for people with chronic pain.

As for his own work, he continues to dream big and strives to do more. Kuluva has a history of incorporating charity and social change in his work as a fashion designer.

I was hoping to inspire change with the collection that I did. I hope that it opens eyes and spreads awareness, Kuluva said.

In an interview for The Mighty, Kuluva explained his CreakyJoints collection by saying, It really shows the joints affected by arthritis. Its an explosion of colors on joints that would light up on tests for arthritis.

Being diagnosed with RA at age 28 could have destroyed his career or his vision for the future. But it didnt.

Kuluva advises other young people diagnosed with illnesses like RA to keep looking forward and not hiding their condition.

As long as you're open and honest with your doctor and your family with what is going on with you and your health, you can get the help you need. An organization like CreakyJoints can help you understand that you may have restrictions, but you can still achieve great things, he said.

Read more: Dolls with disabilities gaining in popularity

Kuluva is doing his part to spread awareness and other designers are, too.

Tommy Hilfiger has designed some adaptive clothing for children with special needs and physical disabilities.

Fashion bloggers have fought back against ableism in fashion shoots. (Like Kylie Jenner and Lady Gaga using gilded wheelchairs as props.)

Madeline Stewart has made headlines as a model with Down syndrome.

New York Fashion Week began to use models with disabilities, including amputee Shaholly Ayers.

Beyonc cast disability activist Jillian Mercado as a model in one of her advertising campaigns.

And many more brands are coming out with adaptive clothing that is fashionable and chic, yet still provides necessary comfort and functionality.

Still, many fashions dont have stylish, easy-to-wear or adaptive alternatives, or inclusive runway shows or advertising campaigns.

The beauty industry also lacks variety when it comes to ergonomic and adaptive options for hairstyling tools and makeup brushes.

But designers like Kuluva think that these baby steps toward progress are working in favor of people with health problems or physical disabilities.

I think the industry will get there, he said.

For now, the Arthritis Foundation has a list of approved arthritis-friendly products with the Ease of Use seal of approval, to help people with arthritis dress themselves more easily. They also have suggested footwear brands and options.

Other websites, like the now-defunct Arthriving site from Aleve, have attempted to catalog the best products to help people with arthritis pain function better when it comes to daily activities like drying their hair, cooking, buttoning a blouse, fastening a bra, or tying their shoes.

While that site is gone, there are many blogs that offer tips for living well with chronic pain or limitations in terms of physical mobility and ability.

Read more:
Fashion for People with Arthritis and Other Painful Conditions - Healthline

Read More...

Huddersfield woman’s new self-help group for arthritis sufferers – Huddersfield Examiner

March 5th, 2017 4:41 pm

Trish Sahin was only in her thirties when she first began to suffer sharp pains in her knees.

At the time she was a hockey player and otherwise fit and well. A year later she was diagnosed with osteoarthritis and her life changed forever.

Today, Trish, 58, a former art and design teacher, is severely disabled. She walks with the aid of sticks and lives in permanent pain. Two years ago she had to give up work as a supply teacher in secondary schools because her mobility was so restricted. According to the Health and Safety Executive up to one third of people with a musculo-skeletal problem such as arthritis retire early, give up work or reduce their hours.

She is far from being alone in her suffering and yet the condition itself can be isolating. Osteoarthritis is the most common form of arthritic disease and affects 8m people in the UK. The nature of the disease means that sufferers can end up feeling depressed and reluctant to make the effort to go out and about.

As Trish, who lives in Clayton West, explains: I know a lot of people like me who suffer like this and end up staying in all day. I get frustrated and very, very down at times. You isolate yourself, so you get lonely. I do have friends who I go out with but I have to remember not to talk about my arthritis because people get sick of hearing about it - even though its on your mind all the time.

In order to tackle the problem Trish has signed up to become a Champion Volunteer for the charity Arthritis Care, which runs a project entitled Living Well With Arthritis.

She is hoping to establish a peer support drop-in group in Kirkburton, at which arthritis patients can get together on a regular basis to share experiences and information. She said: It will get me out of the house and, hopefully, get other people out of the house. Its given me a purpose. The group is for people of all ages. I know of one young girl with arthritis who had two knee replacements by the age of 24.

Arthritis is an umbrella term for a vast array of conditions - from gout and lupus to rheumatoid arthritis, which is an auto-immune disease. Trish also has the auto-immune condition giant cell arteritis, an inflammation of blood vessels in the head. Many arthritic diseases are painful enough to require constant pain medication and the use of anti-inflammatory drugs and steroids.

Trish has had two knee replacements and hip surgery and is on a cocktail of medication, including steroids. A side effect has been weight gain, in itself bad news for arthritis sufferers as excess weight puts strain on joints. She recently joined a slimming club to lose the four stones gained in the last two years since taking steroids, but says shes battling against reduced mobility and an appetite stimulated by the drug.

Arthritis Care would like to hear from other arthritis patients in the area willing to work as volunteers at information and drop-in points (theres one at Dewsbury Hospital), run peer support workshops (like Trish) or offer telephone advice sessions on practical subjects such as diet and exercise, pain management and living aids.

For her own group Trish would like to hear from people able to provide transport so that those without their own vehicles can attend.

I want people to share their experiences, says Trish, so we can compare notes on medication, diet, benefits and pain management, that sort of thing.

Over the last couple of years shes faced practical issues, such as finding a single-storey house (a bungalow provided by Kirklees), getting a blue badge for her car, and accessing disability benefits to top up her pension. She understands the frustrations faced by disabled people undergoing fitness for work assessments. Theres an assumption that you are putting it on, she says, and you can have a good day when youre walking better. But the pain is awful. I lie in bed at night and its a dull, throbbing ache, that stops you sleeping. No-one wants to be like this. I get these really black moods, Im on anti-depressants as well as everything else.

Trish believes there may be a genetic component to her arthritis as other members of her family have developed joint problems. Many types of arthritis have no known cause but osteoarthritis may result from injury, obesity and ageing. While the condition cant be cured, Arthritis Care says that early diagnosis, treatment and good management can delay the progression and ease symptoms. However, a survey conducted by the charity last year found that many people wait two years or more before seeking help with painful joints.

If youd like to become a volunteer for Arthritis Care in the Kirklees area or help Trishs venture contact Emma Marshall, Volunteer Co-ordinator, on 07968624377 or EmmaM@arthritiscare.org.uk

Osteoarthritis can cause joint pain and stiffness; it is more common in women and the elderly. It develops when the cartilage protecting bones changes and erodes.

Rheumatoid arthritis affects 700,000 people in the UK and is an auto-immune condition that causes inflammation of the joints.

There are forms of arthritis that affect children and young people, it is not just a condition of the elderly.

By the year 2030 it is estimated that there will be a 50% increase in the number of people living with arthritic conditions in the UK.

Figures from Arthritis Care show that last year around 1 in 5 of the general population consulted their GP about a musculo-skeletal problem such as arthritis and 7.5m working days were lost because of arthritic conditions.

According to the World Health Organisation arthritis is the leading cause of disability.

Losing excess weight, taking exercise and eating a healthy diet - some sufferers, like Trish, recommend a Mediterranean diet - can all help ease the painful symptoms.

Read more:
Huddersfield woman's new self-help group for arthritis sufferers - Huddersfield Examiner

Read More...

Opinion/Commentary: Global stem cell therapy market to showcase growth – The Daily Progress

March 5th, 2017 4:40 pm

LONDON Technavio analysts forecast the global stem cell therapy market to grow at a compound annual growth rate of close to 37 percent during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global stem cell therapy market for 2017-2021. To determine the market size, the study considers revenue generated from allogenic and autogenic stem cell therapies.

The Americas are the largest regional segment of the global stem cell therapy market, responsible for generating over 56 percent of the total revenue (2016 figures). The region is expected to continue market dominance through the forecast period, driven by increasing demand for stem cell therapy products and investments into R&D.

Technavio analysts highlight the following factors as contributing to the growth of the global stem cell therapy market:

Increase in federal funding in stem cell therapy.

Sapna Jha, one of the lead research analysts at Technavio for medical imaging research, says, Many stem cell research institutes and small companies are involved in cutting-edge R&D and are yielding encouraging results. These institutions are witnessing an increased flow of investments from federal organizations, due to the realization of the importance of regenerative medicine.

The U.S. National Institutes of Health, a major funding government organization invested approximately USD 1.5 billion in stem cell research projects in 2016. Similarly, several state-level organizations such as California Institute for Regenerative Medicine has contributed USD 3 billion to stem cell research in 2014. Such funding will help various research institutes to discover and develop regenerative medicines, which will boost the global regenerative medicine market enormously.

Growing demand for personalized medicine.

The health care sector is creating a high demand for personalized medicine, which could offer game-changing opportunities for the vendors. These medicines offer treatments based on the individual characteristics, needs, and preferences, which will vastly improve the quality of health care. Individuals are increasingly banking their stem cells for future treatments. Research organizations are also extensively exploring ways to develop personalized treatments with stem cells, which could eventually erase the conventional medicine system and help in the effective treatment of various diseases such as diabetes and cancer.

Demand for development of effective drugs for cardiology and degenerative disorders.

There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease, says Sapna.

Researchers are studying and developing approximately 19 product candidates for the treatment of cardiac disorders, with eight of them in Phase III, and six in Phase II.

Technavio is a global technology research and advisory company. This report was made available through The Associated Press.

Continued here:
Opinion/Commentary: Global stem cell therapy market to showcase growth - The Daily Progress

Read More...

Scientists moving ahead with research to resurrect the dead with stem cells – Blastr

March 4th, 2017 6:44 am

A U.S. biotech company is preparing to start experiments using stem cells to try to stimulate 20 brain-dead patients back to life. And no, this isn't an elevator pitch for a sci-fi horror film.

The Mind Unleashed reports the company Bioquark will be trying to use stem cells to regrow and stimulate neurons to bring the patients back from brain death. It works like this: They implant stem cells in the patient's brain while also infusing the spinal cord with chemicals typically used to try and wake up coma patients. Then, hopefully, brain activity is essentially 'jump-started.' The technique is untested, so these experiments will go a long way toward proving (or disproving) the viability of the process.

Bioquark CEO Ira Pastor said they hope to see some results within 2-3 months after treatment begins, with the long-term goal being to develop techniques for brain-dead patients to eventually be able to make a full recovery. Which is certainly a heady, and ethically tricky, goal. You know, and also kind of scary. Ambitious and potentially live-saving, but still a little freaky.

What do you think of the technique? Is this going to revolutionize brain recovery or be the first step toward the T-virus?

(via The Mind Unleashed)

Original post:
Scientists moving ahead with research to resurrect the dead with stem cells - Blastr

Read More...

Page 1,080«..1020..1,0791,0801,0811,082..1,0901,100..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick